Is Vanguard's VB or SPDR's SPSM the Better Small-Cap ETF Buy? Here's What Investors Need to Know.

Vanguard Small‑Cap ETF (VB) and SPDR Portfolio S&P 600 Small Cap ETF (SPSM) both charge an ultra‑low 0.03% expense ratio but differ in scale and composition: VB has $169B AUM and 1,324 holdings versus SPSM's $14B and 607 holdings. As of Feb. 12, 2026 VB has a 1‑yr return of 10.65% (vs SPSM 10.28%), a 5‑yr growth of $1,000 to $1,260 (vs $1,216), dividend yields of 1.27% (VB) and 1.53% (SPSM), betas of 1.23 and 1.19, and 5‑yr max drawdowns of -28.16% and -27.95% respectively. The key tradeoff is VB’s greater diversification and heavier tech exposure (17% vs SPSM’s ~13%)—yielding marginal outperformance but slightly higher volatility—while SPSM offers a narrower, more S&P 600‑tracking small‑cap profile and a marginally higher income yield.

Analysis

Market structure: Vanguard (VB, AUM $169B) is the dominant small‑cap vehicle versus SPSM ($14B) — ~12x AUM — so market‑wide flows will disproportionately land in VB, tightening its bid/ask and compressing tracking error. Winners are broad small‑cap industrials/tech holdings inside VB (higher tech weight 17% vs 13%); losers are thin, idiosyncratic names in SPSM that can be crowded or dumped during outflows. Cross‑asset: a sustained small‑cap bid would steepen credit spreads compression among high‑beta HY credits and lift implied equity vols in single small caps while lowering index vol curves modestly.

Risk assessment: Tail risks are idiosyncratic drawdowns (biotech trial failures like ARWR) and liquidity squeezes in microcaps contained in VB’s larger 1,324 stock universe; SPSM’s S&P 600 index has a profitability screen producing a quality tilt that reduces but does not eliminate drawdown risk (~-28% 5y). Immediate catalysts (days–weeks): monthly flows and ETF rebalances; short term (3‑6 months): Fed rate moves and small‑cap earnings; long term (12+ months): growth cycle and corporate credit conditions. Hidden dependency: index construction (CRSP vs S&P rules) drives sector/quality biases that will magnify performance divergence if growth or rate regime changes.

Trade implications: For a risk‑on tilt, favor VB over SPSM — VB’s broader microcap/tech exposure should outperform in a growth reacceleration; implement a 1–3% tactical overweight to VB for a 3–12 month horizon and hedge with 3‑month 10% OTM put spreads to cap downside. For income/risk‑averse buckets, prefer SPSM or sell 30–60 day covered calls on SPSM to harvest the 1.53% yield plus option carry; consider a relative pair (long VB, short SPSM) sized to 0.5–1% notional to express microcap beta over 3–6 months with a 3% relative stop. Monitor Fed meeting windows (next 30–45 days) before re‑risking.

Contrarian angles: Consensus undervalues the liquidity and tracking advantages of VB’s huge AUM — lower trading costs and easier execution materially improve realized returns vs headline index returns in stress episodes. The market may be underpricing VB’s microcap upside if growth reaccelerates (histor analog: small‑cap outperformance of 12–25% in 12 months post‑rate easing); conversely SPSM’s profitability screen can cause valuation crowding and unexpected single‑name concentration risk. Unintended consequence: chasing SPSM for slightly higher yield (+0.26% differential) risks concentrated idiosyncratic losses that can exceed that carry within weeks.

Key Decisions for Investors

• Establish a tactical 1.5–2.5% overweight in Vanguard Small‑Cap ETF (VB) within 2 weeks to express microcap/tech upside for a 3–12 month horizon; hedge cost by buying a 3‑month 10% OTM put spread (buy 10% OTM, sell 20% OTM) sized to limit downside to ~3–4% of position.
• Initiate a pair trade: long VB / short SPSM (equal notional, start 0.5–1.0% of portfolio) to capture expected microcap outperformance over 3–6 months; set a 3% relative stop‑loss and take profit at +3–6% relative outperformance.
• Cap single small‑cap stock exposure (e.g., ARWR, SOLS, AEIS) at 0.5% portfolio weight and reduce outright small‑cap biotech exposure after any binary catalyst; avoid initiating >1% positions ahead of clinical readouts or FDA decisions within the next 90 days.
• For conservative income buckets, rotate up to SPSM if you need lower tech beta and yield (1.53%): sell 30–60 day covered calls on SPSM to generate ~0.25–0.5% monthly carry while targeting a rollover if shares gap down >5% intraday.
• Reassess positions around two catalysts: the next Fed decision (within 30–45 days) and upcoming small‑cap earnings season (next 6–8 weeks); trim VB exposure by 25–50% if Russell/small‑cap implied vol spikes >40% (signal of stress) or if VB underperforms SPSM by >5% on a month basis.